Biosimilars in rheumatology: out of the laboratory and into practice

Expert Review of Clinical Immunology

Volumn 12, Issue 7, 2016, Pages 697-699

  Rutherford, Andrew I ^a   Galloway, James B ^b  

^a BHF Centre for Regenerative Medicine and BHF Centre of Excellence and the Biomedical Research Centre at Guy s St Thomas NHS Foundation Trust and King s College London   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

anti TNF; Biologic; biosimilar; drug therapies; rheumatoid arthritis

Indexed keywords

BIOSIMILAR AGENT; ETANERCEPT; GENERIC DRUG; INFLIXIMAB;

BIOEQUIVALENCE; CLINICAL PRACTICE; COMPARATIVE STUDY; CYTOTOXICITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNOGENICITY; PHASE 1 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; BIOTECHNOLOGY; PATENT; RHEUMATOLOGY; TRANSLATIONAL RESEARCH; UNITED KINGDOM;

ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; BIOTECHNOLOGY; ETANERCEPT; HUMANS; INFLIXIMAB; PATENTS AS TOPIC; RHEUMATOLOGY; TRANSLATIONAL MEDICAL RESEARCH; UNITED KINGDOM;

EID: 84973167193     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2016.1191946     Document Type: Editorial

References (14)

1. JFC. British National Formulary. 70 ed. London: BMJ Group and Pharmaceutical Press; 2015.
2. Food and Drug Administration. BLA 125544: CT-P13, a proposed biosimilar to Remicade (Infliximab). 2016 Feb 09. [cited 2016 May05]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484859.pdf
3. U.Klotz, A.Teml, M.Schwab Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–660.
4. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 2012. [cited 2016 Feb23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf
5. D.H.Yoo, P.Hrycaj, P.Miranda, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
6. European Medicines Agency. Assessment Report: Remsima. 2013. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf
7. D.H.Yoo, C.Oh, S.Hong, et al. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product. Expert Rev Clin Immunol. 2015;11(Suppl 1):S15–S24.
8. D.H.Yoo, N.Prodanovic, J.Jaworski, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2016 Apr 29. doi:10.1136/annrheumdis-2015-208786. [Epub ahead of print]•• An open label extension study which demonstrates that switching from reference infliximab to the biosimilar CT-P13 is safe an efficacious.
9. W.Park, P.Hrycaj, S.Jeka, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
10. Y.Lee, D.Shin, K.Yea. A phase I pharmacokinetic study comparing SB4, an etanercept biosimilar, and etanercept reference product (Enbrel®) in healthy male subjects. Ann Rheum Dis. 2015;74(Suppl.2):718. doi:10.1136/annrheumdis-2015-eular.2671
11. P.Emery, J.Vencovsky, A.Sylwestrzak, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015 Jul 6. doi:10.1136/annrheumdis-2015-207588. [Epub ahead of print].
12. L.Marshall, T.Hickling, D.Bill, et al. Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration. Ann Rheum Dis. 2016 Mar 31. doi:10.1136/annrheumdis-2016-209502. [Epub ahead of print].
13. P.Emery, J.Vencovský, J.Ghil, et al. Response to: ‘Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al. Ann Rheum Dis. 2016 May 4. doi:10.1136/annrheumdis-2016-209517. [Epub ahead of print].
14. British Society of Rheumatology. Position Statement on Biosimilar Products. 2015 Feb. Available from: http://www.rheumatology.org.uk/includes/documents/cm_docs/2015/b/bsr_biosimilars_position_statement_feb_2015.pdf